Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE combined with apatinib for recurrent hepatocellular carcinoma
ChiCTR1800017333Phase 4Not yet recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Aug 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in hepatocellular carcinoma (HCC), sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoint: progression-free survival. Planned start Aug 2018; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR1800017333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017333.